Emerging treatments for mesothelioma can be modified versions of existing ones or entirely new therapies altogether. New mesothelioma treatments are currently being studied in clinical trials across the country. Examples of emerging mesothelioma treatments include: Immunotherapy Gene therapy Vaccine therapy Stu...
New and old treatments for malignant mesothelioma: not just immunotherapydoi:10.1016/S2213-2600(20)30516-6Anna K NowakThe Lancet Respiratory Medicine
Mesothelioma cancer historically has affected men. But now women comprise nearly one-fourth of all cases and incidence rates among women are on the rise.
Clinical activity was observed with an overall disease control rate of 35% and 4 confirmed responses in mesothelioma, ovarian cancer, atypical lung neuroendocrine tumour, and intrahepatic cholangiocarcinoma. Across all tumours, multimodal analyses of paired patient biopsies pre- and post-treatment ...
Particular attention should be attached to the key points for improved CAR-M therapeutics, such as improving CAR design to maximize macrophage phagocytosis, combining other treatments to achieve synergistic effects, simplifying and optimizing CAR-M manufacturing process, and generating allogeneic or “off...
This review will be a valuable reference for researchers and clinicians working on the development of new treatments for NCDs, specifically those targeting the Nrf2 pathway with natural compounds such as Que. 2. Crosstalk between oxidative stress, inflammation, and NCDs Inflammation and oxidative ...
The 2015 WHO classification of tumors categorized malignant mesothelioma into epithelioid, biphasic (BMM), and sarcomatoid (SMM) for prognostic relevance a... FG Salle,NL Stang,A Nicholson,... - 《Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lu...
as well as EGFR alteration) to test the efficacy of the specific targeted therapy. BATTLE was the first umbrella trial to identify which treatments were most effective for specific genetic subgroups using a biomarker-driven approach. The successful implementation of early umbrella trials showcased the...
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia[J]. Cancer Discov, 2013, 3(12): 1416-1429. doi: 10.1158/2159-8290.CD-13-0350 [7] Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for ...
[147]. Moreover, combinatory treatments that promote T and NK cell function simultaneously to reduce the presence of immunosuppressive cells might also be of value. The use of novel small-molecule inhibitors of PD-1/PD-L1 currently under clinical development might be beneficial because of their ...